Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A national class action in Canada has been commenced against Medtronic Plc (NYSE: MDT) over its MiniMed 630G and 670G insulin pumps. Rochon Genova and Cardill Law commenced the proposed class-action suit against Medtronic, Medtronic MiniMed, and Medtronic of Canada over the insulin pumps approved in Canada in 2016 and 2018.

Medtronic To Face Class Action Suit From Canadian Users Of MiniMed Insulin Pumps

Medtronic is a Dividend Champion and Dividend Aristocrat having raised the dividend for 44 consecutive years. The company is one of the largest pure-play medical device companies in the world.

Medtronic: Time To Add Shares

Medtronic has tightened its focus on health care technology with research and development of artificial-intelligence-based medical devices.

Medical device leader Medtronic joins race to bring AI to health care

RPM International

Walmart

They're among the safest stocks you can invest in from the healthcare, industrial, and retail sectors.

3 Dividend Aristocrats That Have Been Raising Payments for a Combined 140 Years

DUBLIN, Oct. 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced Austin L. Chiang, M.D.

Austin L. Chiang, M.D., M.P.H. joins Medtronic as Chief Medical Officer for Gastrointestinal business

Medtronic Plc (NYSE: MDT) has issued an urgent field safety notice in Europe to warn of its Percept PC Implantable Neurostimulator (INS) issues. The notice's purpose is to inform customers of the potential failure with the Model B35200 Percept PC INS following a cardioversion procedure.

Medtronic Warns On Percept PC Implantable Neurostimulators In Europe

Harder to manage pediatric and adolescent patients achieve 74% Time in Range, and 82% overnight Time in Range, well surpassing clinical consensus guidelines for glycemic control DUBLIN, Oct. 19, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a leading global healthcare technology company, recently announced one-year, real-world clinical data on 3,211 pediatric and adolescent patients with type 1 diabetes 15 years old and below using the MiniMed™ 780G system1 with the Guardian™ Sensor 3. Data on this subset of patients on the system in Europe showed an average Time in Range of 74% — surpassing Clinical Consensus Guidelines and closely mirroring Time in Range for adults at 77%.

Children achieve Time in Range mirroring well-controlled adults for the first time in real-world study of the MiniMed™ 780G system

An important clinical trial will last longer than some expected.

Why Medtronic Fell by Almost 6% on Monday

Company to highlight environmental, social, and governance (ESG) efforts in inaugural ESG Investor Briefing DUBLIN, Oct. 12, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT) today released its fiscal year (FY) 2021 Integrated Performance Report: Engineering Impact  and will share key updates at its inaugural ESG Investor Briefing, to be hosted on Oct. 13, 2021. The company also unveiled its refreshed brand with a new tagline, "Engineering the Extraordinary".

Medtronic announces new ESG targets in its FY21 Integrated Performance Report and unveils refreshed brand

Medtronic plc (NYSE: MDT) has secured European approval for its Hugo surgical robot. Hugo performed its first human procedure in June this year, a minimally invasive prostatectomy in Chile.

Medtronic's Hugo Surgical Robot Wins Regulatory Nod In Europe

Multiple Hospitals Across Europe Set to be the First to Install Hugo™ RAS System and Expand the Benefits of Robotic-Assisted Surgery to Their Patients DUBLIN, Oct. 11, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the Hugo™ robotic-assisted surgery (RAS) system, authorizing the sale of the system in Europe. CE Mark approval is for urologic and gynecologic procedures, which make up about half of all robotic procedures performed today.

Medtronic Hugo™ Robotic-Assisted Surgery System Receives European CE Mark Approval

According to Medtronic (MDT), healthcare systems are better prepared as vaccination rates continue to increase.

Medtronic (MDT) Sees Business Recovery Despite Volume Pressure

The FDA has announced that Medtronic Plc (NYSE: MDT) has expanded the Class I recall of its MiniMed 600 series insulin pumps. Medtronic is offering to replace all MiniMed 600 series insulin pumps that have a clear retainer ring.

Medtronic Expands Recall of MiniMed 600 Series Insulin Pumps

Anthem

Catalent

CVS Health

Pfizer

Teladoc

UnitedHealth Group

Healthcare stocks could take over from energy stocks as top dog during this defensive cycle as yields move higher and tech stocks lose value. The post 7 Healthcare Stocks to Add to Your Portfolio appeared first on InvestorPlace.

7 Healthcare Stocks to Add to Your Portfolio

APA Corporation

AutoZone

CNH Industrial NV

East West Bancorp

Extra Space Storage

Twenty-First Century Fox

General Electric

Uber

Williams-Sonoma

As incredible as it may seem, 2021 is down to the final 90 days of the year. Halloween and the other holidays will soon be upon us, and many investors and traders across Wall Street are a touch anxious over what could be a volatile quarter, especially following September, which was the worst month for stocks since 2020.

BofA Securities Is Out With Its Top 10 Stock Picks for Q4

Medtronic plc (MDT) Management Presents at General Manager Call Series Conference (Transcript)

Bradley Lerman, SVP General Counsel And Corporate Sec at Medtronic (NYSE:MDT), made a large buy and sell of company shares on September 30, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Bradley Lerman exercised options to purchase 49,147 Medtronic shares at a price of $78.00 per share for a total of $3,833,466 on September 30.

SVP General Counsel And Corporate Sec Of Medtronic Trades $10M In Company Stock

DUBLIN, Oct. 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the publication of a study demonstrating, through the use of a Medtronic continuous rhythm monitoring device, that atrial fibrillation (AF) is directly and transiently associated with ischemic stroke. The findings were published online on September 29 in JAMA Cardiology.

Continuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrilation Episodes and Ischemic Stroke

Baxter

Boston Scientific

Hill-Rom Hlds

Intersect ENT

MedTech stocks like Boston Scientific (BSX), Catalent (CTLT) and Baxter (BAX) are likely to solidify businesses on the back of impressive M&As.

MedTech Thrives on M&A Frenzy: 3 Stocks to Focus on

DUBLIN, Sept. 30, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients.

Medtronic Expands Minimally Invasive Spine Surgery Ecosystem with Next-Generation Spinal Technologies

Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.

Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio

Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.

Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure

Medtronic plc (NYSE: MDT) has received CE Mark approval for its radial artery access portfolio, including the Rist 079 Radial Access Guide Catheter and Rist Radial Access Selective Catheter. The Rist 079 Radial Access Guide Catheter is designed to access the neuro vasculature through the radial artery versus the transfemoral artery.

Medtronic's Radial Artery Access Portfolio Approved In Europe

DUBLIN, Sept. 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE Mark approval for its radial artery access portfolio, which includes the Rist™ 079 Radial Access Guide Catheter and Rist™ Radial Access Selective Catheter.

Medtronic Receives CE Mark Approval for Radial Artery Access Portfolio

Apple

Abbott Labs

Amplify Lithium & Battery Technology ETF

Blackrock Inc

Carrier Global

Colgate-Palmolive

Chevron

Invesco DB Commodity Index Tracking Fund

iShares Core S&P 500 ETF

Johnson & Johnson

Coca-Cola

Lowe's

Microsoft

NIKE

ProShares S&P 500 Dividend Aristocrats ETF

Otis Worldwide

PepsiCo

Procter & Gamble

QUALCOMM

Raytheon Technologies

Texas Instruments

Vanguard Dividend Appreciation ETF

Walgreens

The Dividend Aristocrats have historically beat the market with less volatility. Can you improve your odds by paying attention to certain metrics such as quality or safety?

News for Medtronic Stock (MDT)